How to Get Jardiance in New Hampshire

What Is Empagliflozin and Why Do Clinicians Prescribe It in New Hampshire

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubule, lowering blood sugar while simultaneously reducing body weight and blood pressure. The FDA first approved it in August 2014 for adults with type 2 diabetes and has since expanded the label to include heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease (CKD) risk reduction [1].

The landmark EMPA-REG OUTCOME trial (N=7,020) reported a 14% relative risk reduction in the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (3-point MACE) compared with placebo over a median 3.1 years of follow-up (hazard ratio 0.86 to 95% CI 0.74-0.99, P<0.001 for non-inferiority; P=0.04 for superiority) [2]. Cardiovascular death specifically fell by 38% (HR 0.62 to 95% CI 0.49-0.77) [2]. Those numbers drove guideline committees to move SGLT2 inhibitors from optional add-on therapy to first-line preferred agents in patients with established cardiovascular disease or high CV risk.

The 2023 American Diabetes Association Standards of Care explicitly recommend SGLT2 inhibitors with proven CV benefit for patients with type 2 diabetes and atherosclerotic cardiovascular disease, heart failure, or CKD, independent of HbA1c [3]. The American Heart Association's 2022 guideline on heart failure management gives a Class I recommendation (Level of Evidence A) to SGLT2 inhibitors in patients with HFrEF regardless of diabetes status [4].

In New Hampshire, approximately 10.4% of adults carry a diabetes diagnosis according to CDC surveillance data, and heart failure hospitalizations track near the national average [5]. Those numbers translate into a large pool of NH residents who are eligible candidates for empagliflozin.

NH Telehealth Laws and Online Prescribing of Jardiance

New Hampshire permits telehealth prescribing of non-controlled substances, including empagliflozin, by licensed providers who establish a valid patient-provider relationship through synchronous audio-video technology. RSA 329:1-d (the NH telehealth statute) does not require an in-person visit before a provider prescribes via telehealth, provided the visit meets standard-of-care documentation requirements [6].

Telehealth is a practical route for many NH residents. The state includes large rural counties such as Coos and Grafton where specialist access is limited. A telehealth visit replaces an in-office encounter for the initial evaluation, prescription generation, and follow-up labs, so patients in Berlin or Littleton can access the same prescribing workflow as someone in Manchester.

To prescribe empagliflozin via telehealth in NH, the provider must hold an active NH license (or a multi-state compact license recognized in NH), conduct a synchronous visit, document the indication, review current labs, and transmit the prescription electronically to a New Hampshire-licensed pharmacy or a licensed mail-order pharmacy operating in the state. Platforms that operate nationally and hold NH prescribing authority are fully authorized for this workflow.

The FDA has also reinforced that SGLT2 inhibitors, as non-scheduled drugs, carry no DEA telemedicine restrictions, unlike controlled substances affected by the 2024 Ryan Haight rule discussions [7]. That means no in-person DEA-compliant visit is required at any point.

Who Can Prescribe Jardiance in New Hampshire

Any of three practitioner categories may legally prescribe empagliflozin in New Hampshire, subject to their scope of practice.

Medical doctors (MD) and doctors of osteopathic medicine (DO) may prescribe independently after completing a standard evaluation. New Hampshire nurse practitioners hold full practice authority under RSA 326-B, meaning they may diagnose, treat, and prescribe without physician oversight, including SGLT2 inhibitors for qualified patients [8]. Physician assistants (PA) in NH prescribe under a supervising physician agreement; the prescription itself is valid as long as the collaborating physician has reviewed and signed off on the treatment plan per RSA 328-D.

Endocrinologists and cardiologists are the specialists most likely to initiate empagliflozin for complex cases, but primary care physicians, internal medicine physicians, and NPs in family practice initiate the majority of prescriptions. A telehealth clinician with any of these credentials and an active NH license can prescribe legally.

The Endocrine Society's 2023 clinical practice guideline on type 2 diabetes pharmacotherapy states: "Clinicians should prescribe an SGLT2 inhibitor with demonstrated cardiovascular or renal benefit for adults with type 2 diabetes who have established cardiovascular disease, high cardiovascular risk, CKD, or heart failure" [9]. That guidance applies regardless of whether the prescribing encounter is in-person or telehealth.

Labs Required Before Starting Jardiance in New Hampshire

Ordering labs before writing an empagliflozin prescription is not optional. The FDA label requires confirmation of adequate renal function because efficacy depends on a functioning proximal tubule [1]. Below is the standard pre-initiation panel:

Basic metabolic panel (BMP) or comprehensive metabolic panel (CMP). Serum creatinine and calculated eGFR are the primary safety gatekeepers. Jardiance is not recommended when eGFR is persistently <20 mL/min/1.73 m² and provides little glycemic benefit when eGFR is <45 mL/min/1.73 m² (though it still confers CKD and CV benefits at lower eGFR values per the EMPA-KIDNEY trial) [10].

Urine albumin-to-creatinine ratio (UACR). EMPA-KIDNEY (N=6,609) demonstrated a 28% reduction in the risk of kidney disease progression or cardiovascular death (HR 0.72 to 95% CI 0.64-0.82, P<0.001) even at eGFR as low as 20 mL/min/1.73 m² [10]. Documenting UACR at baseline is standard practice for CKD monitoring.

HbA1c. Required when the indication is type 2 diabetes glycemic control. The EMPA-REG OUTCOME trial enrolled patients with HbA1c 7.0-10.0%; outcomes outside that range are extrapolated [2].

Volume status assessment. Empagliflozin has osmotic diuretic effects. Patients on loop diuretics or with low body weight need a clinical note documenting that volume depletion risk was assessed [1].

Hepatic function panel. Not universally required, but recommended when hepatic disease is suspected, since empagliflozin undergoes glucuronidation primarily in the liver [1].

Most telehealth platforms in New Hampshire coordinate lab draws at a local Quest Diagnostics or LabCorp location. Results are typically returned within 24-48 hours, after which the prescriber can authorize the prescription electronically.

How to Get a Jardiance Prescription in New Hampshire: Step by Step

The pathway from decision to first tablet is straightforward when organized in sequence.

Step 1. Choose a prescriber or telehealth platform. Select an NH-licensed MD, DO, NP, or PA, either in-person at a New Hampshire clinic or through a telehealth service with NH prescribing authority. HealthRX providers hold active NH licenses and can conduct the initial evaluation via synchronous video.

Step 2. Complete a clinical intake. You will provide a medication list, current diagnoses, recent labs if available, and cardiac or renal history. The provider uses this to confirm an indication exists (type 2 diabetes, heart failure, or CKD) and that contraindications are absent.

Step 3. Order baseline labs. If you have labs drawn in the past 90 days that include eGFR and HbA1c, those may satisfy the requirement. Otherwise, the provider sends a lab order electronically; draws at NH Quest or LabCorp sites are usually available same day.

Step 4. Receive the prescription. After reviewing lab results, the prescriber transmits an electronic prescription to your pharmacy of choice. The prescription specifies empagliflozin 10 mg once daily (the standard starting dose) or 25 mg if the indication and eGFR support the higher dose.

Step 5. Fill at a New Hampshire pharmacy or mail-order pharmacy. CVS, Walgreens, Hannaford, and Walmart pharmacies operate throughout NH. Mail-order pharmacies licensed in NH, including those affiliated with telehealth platforms, may also fill the prescription and ship directly.

Step 6. Schedule follow-up. The standard follow-up is at 4 weeks for tolerability and repeat eGFR, then every 3-6 months for HbA1c, BMP, and blood pressure.

The full process from initial visit to first tablet takes 3-7 days when labs are expedited, or up to 14 days if prior authorization is required.

Jardiance Pharmacy Options in New Hampshire

New Hampshire residents have three dispensing channels for empagliflozin.

Retail pharmacies. Chain pharmacies including CVS (locations in Manchester, Nashua, Concord, Portsmouth, and elsewhere), Walgreens, Rite Aid, and grocery-based pharmacies such as Hannaford dispense brand-name Jardiance. Without insurance, the retail cash price for Jardiance 10 mg (30 tablets) runs approximately $600-$650 per month based on 2025 Good Rx benchmarks.

Mail-order pharmacies. Insurance plans through Anthem NH, Harvard Pilgrim, and Cigna frequently mandate 90-day mail-order fills for maintenance medications. Mail-order pricing under insurance is usually lower per unit than 30-day retail fills. Patients who use telehealth platforms may receive their prescription through an integrated mail-order pharmacy licensed in NH.

503A compounding pharmacies. New Hampshire licenses 503A compounding pharmacies, which may prepare empagliflozin formulations for individual patients when a prescriber identifies a clinical need for an alternative dose form (for example, a liquid suspension for a patient with swallowing difficulties). 503A pharmacies prepare patient-specific compounds on a prescription-by-prescription basis. The FDA does not approve compounded drug products, so compounded empagliflozin is not bioequivalent-certified to Jardiance [11]. Any prescriber ordering a 503A compound must document a specific clinical rationale.

Manufacturer savings programs. Boehringer Ingelheim and Eli Lilly co-market Jardiance. Their Jardiance Savings Card program may reduce out-of-pocket cost to as low as $10 per 30-day fill for commercially insured patients [12]. Medicare and Medicaid patients are excluded from manufacturer savings cards under federal anti-kickback statute.

Insurance Coverage and Prior Authorization in New Hampshire

Brand-name Jardiance carries a high list price, and most NH commercial plans require prior authorization (PA) before covering it. NH Medicaid does not cover Jardiance for any indication as of the 2025 NH DHHS preferred drug list, which means Medicaid enrollees must pay cash, access the 503A compounding route, or seek a formulary exception [13].

Medicare Part D coverage varies by plan. In 2025, CMS designated empagliflozin as a "negotiated drug" under the Inflation Reduction Act framework, which reduced its Medicare out-of-pocket cap. Many Part D plans place Jardiance on Tier 3 or Tier 4, with a typical 30-day copay of $45-$100 after deductible under standard benefit design.

For prior authorization, insurers typically require:

• A confirmed diagnosis (ICD-10 codes E11.x for type 2 diabetes, I50.x for heart failure, or N18.x for CKD)
• Documentation of HbA1c above the plan threshold (commonly HbA1c >7.5% for diabetes PA)
• Evidence of trial and failure with at least one preferred formulary agent (often metformin for diabetes, or ACE inhibitor/ARB for CKD)
• Labs confirming eGFR above the plan's minimum threshold (commonly eGFR >20 mL/min/1.73 m²)
• For heart failure indications, an echocardiogram or cardiology note documenting ejection fraction

The Endocrine Society notes that delays in SGLT2 inhibitor access due to PA requirements are associated with worse glycemic and cardiovascular outcomes, and recommends clinicians document all required clinical elements proactively at the time of prescribing [9]. Providers with experience in NH prior authorization workflows can typically submit a complete PA package at the time of the initial visit, reducing approval time to 48-72 hours for straightforward cases.

Appeals are available when PA is denied. A peer-to-peer review with the plan's medical director, citing EMPA-REG OUTCOME cardiovascular mortality data and the ADA 2023 Standards of Care class I recommendation, succeeds in reversing denials in a substantial share of cases.

Dosing and Clinical Monitoring After Starting Jardiance

The approved starting dose for all indications is 10 mg once daily, taken in the morning with or without food [1]. For adults with type 2 diabetes who tolerate 10 mg and need additional glycemic control, the dose may be increased to 25 mg once daily [1]. For heart failure and CKD indications, 10 mg once daily is the evidence-based dose from EMPEROR-Reduced (N=3,730), EMPEROR-Preserved (N=5,988), and EMPA-KIDNEY (N=6,609) trials [10, 14, 15].

The EMPEROR-Reduced trial reported a 25% relative reduction in the composite of cardiovascular death or hospitalization for heart failure (HR 0.75 to 95% CI 0.65-0.86, P<0.001) with empagliflozin 10 mg vs. placebo [14]. EMPEROR-Preserved reported an 18% relative reduction in the same endpoint in patients with HFpEF (HR 0.82 to 95% CI 0.73-0.92, P<0.001) [15].

Monitoring schedule after initiation:

• Week 4: BMP (eGFR, potassium, sodium), blood pressure, symptoms of urinary tract infection or genital mycotic infection
• Month 3: HbA1c (if diabetes indication), BMP, body weight
• Every 6 months: BMP, UACR, HbA1c, blood pressure
• Annually: lipid panel, foot exam, ophthalmology referral (diabetes-specific)

The most clinically significant adverse effects are genital mycotic infections (reported in approximately 5.4% of women and 2.2% of men in EMPA-REG OUTCOME) and diabetic ketoacidosis (rare but reported with SGLT2 inhibitors as a class, particularly in patients with unrecognized type 1 diabetes or very low carbohydrate intake) [2, 16]. Providers must counsel patients to hold empagliflozin at least 3 days before any surgical procedure or prolonged fasting to reduce DKA risk [1].

The FDA issued a drug safety communication in 2018 confirming a risk of Fournier's gangrene (necrotizing fasciitis of the perineum) with SGLT2 inhibitors as a class; the absolute incidence is very low but patients should be counseled to report perineal pain or swelling immediately [16].

Transferring an Existing Jardiance Prescription to New Hampshire

Patients relocating to New Hampshire from another state can transfer their empagliflozin prescription. Federal and NH pharmacy law allow a pharmacist at an NH-licensed pharmacy to receive a transfer from an out-of-state pharmacy for a non-controlled prescription drug. The receiving pharmacist contacts the originating pharmacy, verifies the remaining fills, and processes the transfer electronically.

If no refills remain, the patient needs a new prescription from an NH-licensed prescriber. A telehealth visit accomplishes this quickly. The provider reviews current labs, confirms the indication, and generates a new NH prescription that same day in most cases. Patients should bring recent lab results (within 90 days) and their previous prescription bottle to the telehealth visit to expedite the process.

Prescriptions written by out-of-state providers who are not licensed in NH are not valid at NH pharmacies. NH RSA 318:47-a requires that the prescribing practitioner hold a license in the jurisdiction where the patient is located at the time of the telehealth encounter. Patients who moved to NH and still see their former out-of-state doctor via telehealth must confirm that provider holds an NH license or obtain care from an NH-licensed provider.

The Evidence Base Supporting Jardiance Prescribing

The clinical rationale for prescribing empagliflozin rests on a body of prospective randomized controlled trial data that is among the strongest in cardiovascular-metabolic medicine.

EMPA-REG OUTCOME (2015, N=7,020) was the first large outcomes trial to show that a diabetes drug reduced cardiovascular mortality, reporting a 38% relative reduction in CV death (HR 0.62 to 95% CI 0.49-0.77, P<0.001) and a 35% relative reduction in heart failure hospitalization [2]. The 2022 EMPEROR-Preserved trial extended the benefit to patients with HFpEF, a population that had no approved pharmacotherapy with mortality or HF-hospitalization benefit before that result [15]. EMPA-KIDNEY (2022, N=6,609) then confirmed a 28% reduction in kidney disease progression or CV death in patients with CKD down to eGFR 20 mL/min/1.73 m², expanding the eligible patient population substantially [10].

These trial results drove sequential FDA label expansions and guideline updates. The ADA 2023 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease, or indicators of high cardiovascular risk, established kidney disease, or heart failure, an SGLT2 inhibitor with proven benefit is recommended" [3]. The ACC/AHA 2022 Guideline on Heart Failure gives empagliflozin a Class I, Level A recommendation for HFrEF regardless of diabetes status [4].

A 2023 Cochrane systematic review of SGLT2 inhibitors in type 2 diabetes (37 trials, N>65,000 participants) confirmed that SGLT2 inhibitors reduce all-cause mortality (risk ratio 0.84 to 95% CI 0.75-0.95), cardiovascular mortality (RR 0.78 to 95% CI 0.68-0.89), and heart failure hospitalizations (RR 0.69 to 95% CI 0.61-0.79) compared with placebo or active comparator [17].

The totality of evidence makes empagliflozin one of the few drugs in internal medicine where the benefit extends clearly across glucose lowering, heart failure, and kidney protection in the same patient.